Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
J Infect Dis
; 222(7): 1103-1107, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: covidwho-663915
ABSTRACT
The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Neumonía Viral
/
Leucemia Linfocítica Crónica de Células B
/
Adenosina Monofosfato
/
Infecciones por Coronavirus
/
Síndrome Respiratorio Agudo Grave
/
Alanina
/
Betacoronavirus
Tipo de estudio:
Reporte de caso
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Humanos
/
Masculino
/
Middle aged
Idioma:
Inglés
Revista:
J Infect Dis
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Infdis
Similares
MEDLINE
...
LILACS
LIS